Nuvalent Granted FDA Breakthrough Therapy Designation for Non–Small Cell Lung Cancer Drug
NVL-520 is a novel, brain-penetrant, ROS1-selective tyrosine kinase inhibitor under evaluation for patients with metastatic ROS1-positive non–small cell lung cancer.